6 days ago
Pfizer shares jump over 2% after launch of next-gen 20-valent pneumococcal vaccine in India
By Aditya Bhagchandani Published on August 12, 2025, 09:40 IST
Shares of Pfizer Limited rose 2.07% to Rs 5,165.50 on Tuesday, August 12, following the company's announcement of the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for adults in India. The stock traded in a range of Rs 5,098.50 to Rs 5,200.00 during the session, with a market capitalization of Rs 2.36 lakh crore and a price-to-earnings ratio of 30.79.
Launched on August 11, 2025, PCV20 is designed to protect against 20 clinically relevant serotypes of Streptococcus pneumoniae, offering the broadest coverage among conjugate vaccines available in India. Approved for adults aged 18 years and older, it is administered as a single-dose shot, potentially eliminating the need for a second dose.
Pfizer stated that the vaccine will help address the growing need for adult immunization, especially among those over 50 years of age and individuals with chronic conditions such as asthma, COPD, chronic kidney disease, and diabetes. The company noted that the introduction of PCV20 builds on its 25-year legacy in pneumococcal vaccine innovation and strengthens its commitment to preventive healthcare in India.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
